You just read:

Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

News provided by

Tocagen Inc.

May 14, 2018, 08:00 ET